Division of General and Gastrointestinal Surgery, Department of General and Gastrointestinal Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Ann Surg Oncol. 2021 Jun;28(6):3408-3414. doi: 10.1245/s10434-020-09281-0. Epub 2020 Oct 26.
Tumor border configuration (TBC) is a prognostic factor in colorectal adenocarcinoma; however, the significance of TBC is not well-documented in colon adenocarcinoma alone.
Our aim was to study the effect of TBC on overall and disease-free survival in stage II and III colon adenocarcinoma.
We included patients with stage II and III colon adenocarcinoma who were surgically treated at a tertiary medical center between 2004 and 2015, to ensure long-term follow-up. Patients were stratified into four groups based on stage and TBC. A Cox regression was used to model the relationship of groups while accounting for relevant confounders.
The cohort consisted of 700 patients (371 stage II and 329 stage III). Infiltrating TBC was statistically significantly associated with stage (p < 0.001) and extramural vascular invasion (p < 0.001), but not histologic grade (p = 0.7). Compared with pushing TBC, infiltrating TBC increased the hazard of death by a factor of 1.8 [95% confidence interval (CI) 1.4-2.4; p < 0.001] and 1.7 (95% CI 1.3-2.2; p < 0.001). The hazard of death in patients with stage II disease (infiltrating TBC) or stage III disease (pushing TBC) was not significantly different (adjusted hazard ratio 1.1, 95% CI 0.7-1.7; p = 0.8).
Infiltrating TBC is a high-risk feature in patients with stage II and III colon adenocarcinoma. Stage II disease patients with infiltrating TBC and who are node-negative should be considered for adjuvant chemotherapy.
肿瘤边界形态(TBC)是结直肠腺癌的一个预后因素;然而,TBC 在单纯结肠癌中的意义尚未得到充分证实。
本研究旨在探讨 TBC 对 II 期和 III 期结肠癌患者总生存和无病生存的影响。
我们纳入了 2004 年至 2015 年在一家三级医疗中心接受手术治疗的 II 期和 III 期结肠癌患者,以确保长期随访。根据分期和 TBC 将患者分为四组。使用 Cox 回归模型来模拟组间关系,并考虑到相关混杂因素。
该队列包括 700 例患者(II 期 371 例,III 期 329 例)。浸润性 TBC 在统计学上与分期(p<0.001)和血管外侵犯(p<0.001)显著相关,但与组织学分级无关(p=0.7)。与推进性 TBC 相比,浸润性 TBC 使死亡风险增加 1.8 倍(95%CI 1.4-2.4;p<0.001)和 1.7 倍(95%CI 1.3-2.2;p<0.001)。在 II 期疾病(浸润性 TBC)或 III 期疾病(推进性 TBC)患者中,死亡风险无显著差异(调整后的危险比 1.1,95%CI 0.7-1.7;p=0.8)。
浸润性 TBC 是 II 期和 III 期结肠癌患者的高危特征。无淋巴结转移的 II 期浸润性 TBC 患者应考虑辅助化疗。